310 related articles for article (PubMed ID: 36046351)
21. Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed?
Agarwal A; Spath D; Sherris DA; Kita H; Ponikau JU
Clin Rev Allergy Immunol; 2020 Oct; 59(2):141-149. PubMed ID: 31073812
[TBL] [Abstract][Full Text] [Related]
22. Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai).
Hong HY; Chen TY; Yang QT; Sun YQ; Chen FH; Lou HF; Wang HT; Yu RL; An YF; Liu F; Wang TS; Lu MP; Qiu QH; Wang XD; Chen JJ; Meng CD; Xie ZH; Meng J; Zeng M; Xu CL; Wang Y; Yang YC; Zhang WT; Tang J; Yang YL; Xu R; Yu GD; Shi ZH; Wei X; Ye HP; Sun YN; Yu SQ; Zhang TH; Yong J; Hang W; Xu YT; Xu Y; Tan GL; Sun N; Yang G; Li YJ; Ye J; Zuo KJ; Zhang LQ; Wang XY; Yang AN; Xu YX; Liao W; Fan YP; Li HB
ORL J Otorhinolaryngol Relat Spec; 2023; 85(3):128-140. PubMed ID: 37019094
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
24. The Role of Biologics in the Treatment of Nasal Polyps.
Franzese CB
Immunol Allergy Clin North Am; 2020 May; 40(2):295-302. PubMed ID: 32278452
[TBL] [Abstract][Full Text] [Related]
25. The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye.
Demir M; Tunakan Dalgic C; Mete Gokmen EN; Savas R; Eroglu S; Ozden G; Orcen C; Pacaci Cetin G; Arslan B; Bilgir F; Bulut G; Akcam NY; Ozgul S; Cerci P; Coskun R; Gode S; Yilmaz I; Sin AZ
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541174
[No Abstract] [Full Text] [Related]
26. Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps.
Borish L; Cohen NA; Chupp G; Hopkins C; Wagenmann M; Sousa AR; Smith SG; Silver J; Yang S; Mayer B; Yancey SW; Chan RH; Fokkens W
Ann Allergy Asthma Immunol; 2022 Aug; 129(2):160-168. PubMed ID: 35398492
[TBL] [Abstract][Full Text] [Related]
27. Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review.
Rahavi-Ezabadi S; Zhou S; Lee SE; Ference E; Magit A; Leuin S; Mohamed K; Rezaei N; Patel VA
Otolaryngol Head Neck Surg; 2024 Mar; ():. PubMed ID: 38488239
[TBL] [Abstract][Full Text] [Related]
28. Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps.
Mandl HK; Miller JE; Beswick DM
Otolaryngol Clin North Am; 2024 Apr; 57(2):225-242. PubMed ID: 37684154
[TBL] [Abstract][Full Text] [Related]
29. Biologics in allergic rhinitis.
Bayar Muluk N; Cingi C
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
[TBL] [Abstract][Full Text] [Related]
30. The role of biologics in chronic rhinosinusitis: a systematic review.
Iqbal IZ; Kao SS; Ooi EH
Int Forum Allergy Rhinol; 2020 Feb; 10(2):165-174. PubMed ID: 31869863
[TBL] [Abstract][Full Text] [Related]
31. Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy.
Papacharalampous GX; Constantinidis J; Fotiadis G; Zhang N; Bachert C; Katotomichelakis M
Int Forum Allergy Rhinol; 2024 Jan; 14(1):96-109. PubMed ID: 37394893
[TBL] [Abstract][Full Text] [Related]
32. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
[TBL] [Abstract][Full Text] [Related]
33. Otitis media in severe asthma associated with chronic rhinosinusitis with nasal polyps: a new therapeutic target for biologics.
Bartier S; Béquignon E; Thibaut de Ménonville C; Verillaud B; Evrard D; Léger M; Papon JF; Coste A; Taillé C
J Asthma; 2023 Jan; 60(1):139-144. PubMed ID: 35073225
[No Abstract] [Full Text] [Related]
34. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
35. Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps.
Kartush AG; Schumacher JK; Shah R; Patadia MO
Am J Rhinol Allergy; 2019 Mar; 33(2):203-211. PubMed ID: 30587005
[TBL] [Abstract][Full Text] [Related]
36. Biologics for Nasal Polyps: Synthesizing Current Recommendations into a Practical Clinical Algorithm.
Godse NR; Keswani A; Lane AP; Lee SE; Sindwani R
Am J Rhinol Allergy; 2023 Mar; 37(2):207-213. PubMed ID: 36848277
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD.
Brkic FF; Liu DT; Klimbacher R; Campion NJ; Bartosik TJ; Vyskocil E; Stanek V; Tu A; Arnoldner T; Bangert C; Gangl K; Eckl-Dorna J; Schneider S
Rhinology; 2023 Aug; 61(4):320-327. PubMed ID: 37515811
[TBL] [Abstract][Full Text] [Related]
38. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review.
Aldajani A; Alroqi A; Alromaih S; Aloulah MO; Alsaleh S
Am J Otolaryngol; 2022; 43(6):103615. PubMed ID: 36057193
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada.
Yong M; Kirubalingam K; Desrosiers MY; Kilty SJ; Thamboo A
Allergy Asthma Clin Immunol; 2023 Oct; 19(1):90. PubMed ID: 37838713
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
